According to May's employment situation report (NFP), the U.S. economy added 272,000 jobs during the month. The healthcare industry took down 68,300 employees, or roughly 25.1%. More than that, Janus Henderson, Eli Lilly's largest shareholder, decided to boost its already sizeable stake in the stock in the past quarter. A 7.3% boost as of May 2024 brought the asset manager's position up to $2.8 billion today. There's always a good reason for markets to push stocks near their 52-week highs. Investors can now ...

Editor's note: Seeking Alpha is proud to welcome Evan Urbanski as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Trevor Williams Pixabay via Pexels KEY HIGHLICHTS → Current guidance suggests revenues between $292 million for Q2 24 (40%-43% YoY growth) and FY 2024 revenues at between $1.2 billion and $1.3 billion (38%-41% Y ...

"You have to be a really good student of the business and understand it inside and out and understand the industry," she told CNBC in an interview before her departure announcement. "Only when we understand the full system, can we navigate it well so that we bring value to it…That's my role as CFO." Eli Lilly's boom in revenue has allowed the company to invest heavily to scale up manufacturing, which will eventually get more medicine into patients' hands, Ashkenazi said. Ashkenazi, who will step in as the n ...

Key Points Him & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand and generic versions of Pfizer Inc. NYSE: PFE Viagra (Sildenafil) and Eli Lilly & Co. NYSE: LLY Cialis (Tadalafil). The company has since expanded its treatments to include hair loss, skincare, behavioral health and weight loss solutions. Shares soared on its announcement of offering compounded GLP-1 ( ...

GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK study, in both cases at 12 weeks GSBR-1290 demonstrated generally favorable safety and tolerability results with low AE-related study discontinuations Pharmacokinetic data support dose proportional exposure and once-daily oral dosing of GSBR-1290 36-week Phase 2b study in obesity on track to begin in ...

As weight-loss drugs are gaining popularity, a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everything investors need to know about this new weight-loss focused exchange-traded fund (ETF) before investing in OZEM stock below! OZEM ETF Details Roundhill GLP 1 & Weight Loss ETF has stakes in both Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). These are the makers of weight-loss drugs Ozempic, Wegovy and Moun ...

For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had become a grueling task. She'd tried five different programs in her life and never found lasting results. Her luck started to change last year, when she saw a promotion on Instagram for the Ro Body Program, a new offering from online health startup Ro. The ad said eligible patients could get prescribed GLP-1s, the buzzy class of obesity treatments that's turned into a booming business in recent years. In this article Paten ...

Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Copenhagen, Denmark, 23 May 2024 – Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced topline results from the DREAM trial (Dapiglutide for the Treatment of Obesity), the investigat ...

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK, May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs. "OZEM ...

Formulations to be marketed as "Slim" and "Trim" as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide ("Slim") and Tirzepatide ("Trim") to ...